The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced that it has recently made several dozen awards to further strengthen the nations biodefense and emerging disease research capabilities. The new awards include grants totaling approximately $87 million for the construction of four biosafety level-3 (BSL-3) laboratories as well as two five-year contracts totaling approximately $60 million to support the development of a vaccine against tularemia, a potential agent of bioterror.
Devising medical countermeasures against biological threats, whether they arise naturally or are the result of deliberate human action, is a top priority for NIAID, says NIAID director Anthony S. Fauci, MD. These new awards support research needed to better understand and defend against disease-causing microbes and provide funds to construct facilities where such research can be performed safely.
Regional Biocontainment Laboratories
The four new labs will join nine other NIAID-funded BSL-3 labs in the Institutes Regional Biocontainment Laboratory (RBL) program. In 2002, a panel of experts convened to provide guidance to NIAID on its biodefense agenda cited insufficient BSL-3 and BSL-4 space as a major barrier to research progress. As part of its response, NIAID established the RBL program to fund the design, construction and commissioning of state-of-the-art BSL-3 labs at sites spanning the country. The institutions receiving the new awards and the principal investigators are as follows:
George Mason University, Manassas, Va./ Charles Bailey, PhD
Tufts University, North Grafton, Mass./ Sawkat Anwer, DMVH, PhD
University of Louisville, Ky./ Nancy Martin, PhD
University of Hawaii at Manoa/ James Gaines, PhD
Tularemia Vaccine Contracts
Two contracts totaling approximately $60 million have been awarded to the University of New Mexico (C. Rick Lyons, MD, principal investigator) and to DVC LLC, Frederick, Md. (Robert House, PhD, principal investigator) to support research to identify and evaluate new tularemia vaccine candidates. Tularemia, a bacterial disease, is also known as rabbit fever; symptoms include high fever, chills, aches and swollen lymph glands. Tularemia usually can be successfully treated with antibiotics. However, the bacterium that causes tularemia is regarded by experts as a potential agent of bioterror because, if aerosolized, it could cause widespread cases of more serious disease, including severe respiratory illness and systemic infections, and even death.
Additional Biodefense Research Awards
In addition to those described above, NIAIDs Fiscal Year 2005 biodefense awards include
-- Challenge Grant program awards to support further development of previously identified therapeutics, vaccines, and diagnostics against NIAID Category A, B and C priority pathogens including anthrax, smallpox and viruses that cause pandemic influenza
-- Cooperative Research program awards to stimulate research requiring multidisciplinary effort to advance promising candidate vaccines, therapeutics and other products through the product development pathway
-- Small Business Biodefense program awards
Source: National Institutes of Health
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.